Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses
Author:
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),General Medicine
Link
http://link.springer.com/content/pdf/10.1186/s12883-015-0450-x.pdf
Reference54 articles.
1. Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, Rieckmann P, et al. EFNS guideline on treatment of multiple sclerosis relapses: Report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol. 2005;12:939–46.
2. Miller DM, Weinstock-Guttman B, Bethoux F, Lee JC, Beck G, Block V, et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler. 2000;6:267–73.
3. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23–43.
4. Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid-induced adverse events in adults: Frequency, screening and prevention. Drug Saf. 2007;30:861–81.
5. Gutkowski K, Chwist A, Hartleb M. Liver injury induced by high-dose methylprednisolone therapy: A case report and brief review of the literature. Hepat Mon. 2011;11:656–61.
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Sección II: Tratamiento de los brotes en esclerosis múltiple<br>Capítulo 1<br>Tratamiento con glucocorticoides;Neurología, Neurocirugía y Psiquiatría;2023
2. Predicting Regulatory Product Approvals Using a Proposed Quantitative Version of FDA’s Benefit–Risk Framework to Calculate Net-Benefit Score and Benefit–Risk Ratio;Therapeutic Innovation & Regulatory Science;2020-07-08
3. Causal Evidence and Dispositions in Medicine and Public Health;International Journal of Environmental Research and Public Health;2020-03-11
4. Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients;BMC Neurology;2019-07-20
5. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double‐blind, non‐inferiority trial;European Journal of Neurology;2018-11-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3